170 related articles for article (PubMed ID: 32425386)
1. Promising Response to Thalidomide in Symptomatic β-Thalassemia.
Yassin AK
Indian J Hematol Blood Transfus; 2020 Apr; 36(2):337-341. PubMed ID: 32425386
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide for Patients with β-Thalassemia: A Multicenter Experience.
Yang K; Wu Y; Zhou Y; Long B; Lu Q; Zhou T; Wang L; Geng Z; Yin X
Mediterr J Hematol Infect Dis; 2020; 12(1):e2020021. PubMed ID: 32395210
[TBL] [Abstract][Full Text] [Related]
3. Marital status and paternity in patients with Transfusion- Dependent Thalassemia (TDT) and Non Transfusion-Dependent Thalassemia (NTDT): an ICET - A survey in different countries.
De Sanctis V; Soliman AT; El-Hakim I; Christou S; Mariannis D; Karimi M; Ladis V; Kattamis A; Daar S; Yassin M; Canatan D; Galati MC; Raiola G; Campisi S; Kakkar S; Kaleva V; Saki F; Ellinides A; Pikis G; Christodoulides C; Abdulla M; Di Maio S; Theodoridis C; Elsedfy H; Kattamis C
Acta Biomed; 2019 Sep; 90(3):225-237. PubMed ID: 31580308
[TBL] [Abstract][Full Text] [Related]
4. Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.
Bhurani D; Kapoor J; Yadav N; Khushoo V; Agrawal N; Ahmed R; Arora JS; Mehta P
Ann Hematol; 2021 Jun; 100(6):1417-1427. PubMed ID: 33811502
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of decitabine as hemoglobin F inducer in HbE/β-thalassemia.
Kalantri SA; Ray R; Chattopadhyay A; Bhattacharjee S; Biswas A; Bhattacharyya M
Ann Hematol; 2018 Sep; 97(9):1689-1694. PubMed ID: 29740685
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia.
Chandra J; Parakh N; Sidharth ; Singh N; Sharma S; Goel M; Pemde H
Indian Pediatr; 2021 Jul; 58(7):611-616. PubMed ID: 34315832
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Thalidomide Treatment in Children With Transfusion Dependent β-Thalassemia: A Retrospective Clinical Study.
Li X; Hu S; Liu Y; Huang J; Hong W; Xu L; Xu H; Fang J
Front Pharmacol; 2021; 12():722502. PubMed ID: 34456732
[No Abstract] [Full Text] [Related]
8. [Predictors of Hematologic Responses in Patients with Non-Transfusion-Dependent β-Thalassemia Receiving Thalidomide Therapy].
Yang K; Yin XL; Liu XD; Hua F; Peng W; Li L; Chen K; Zhang J; Luo S; Xiao J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1519-1526. PubMed ID: 36208259
[TBL] [Abstract][Full Text] [Related]
9. Magnitude of Bone Disease in Transfusion-Dependent and Non-Transfusion-Dependent β-Thalassemia Patients.
Shamoon RP; Yassin AK; Omar N; Saeed MD; Akram R; Othman NN
Cureus; 2024 Mar; 16(3):e56012. PubMed ID: 38606231
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
[TBL] [Abstract][Full Text] [Related]
11. Investigating the Efficacy and Safety of Thalidomide for Treating Patients With
Lu Y; Wei Z; Yang G; Lai Y; Liu R
Front Pharmacol; 2021; 12():814302. PubMed ID: 35087410
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia.
Winichakoon P; Tantiworawit A; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Norasetthada L; Charoenkwan P
Anemia; 2015; 2015():793025. PubMed ID: 26664743
[TBL] [Abstract][Full Text] [Related]
13. Non-transfusion dependent thalassemia is independently associated with higher alloimmunization risk than transfusion dependent thalassemia and would benefit the most from extended red cell antigen-matching.
Ang AL; Lim CY; Ng WY; Lam JCM
Transfusion; 2021 Sep; 61(9):2566-2577. PubMed ID: 34258773
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Blood Transfusion on Growth of Patients with Hb E/β-Thalassemia.
Chuansumrit A; Sirachainan N; Kitpoka P; Kadegasem P; Songdej D; Sasanakul W; Wongwerawattanakoon P
Hemoglobin; 2019; 43(4-5):264-272. PubMed ID: 31760834
[TBL] [Abstract][Full Text] [Related]
15. The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients.
Yang K; Wu Y; Ma Y; Xiao J; Zhou Y; Yin X
Blood Cells Mol Dis; 2020 Sep; 84():102442. PubMed ID: 32387854
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to Hydroxyurea: A Single-Center Experience.
Nag A; Radhakrishnan VS; Kumar J; Bhave S; Mishra DK; Nair R; Chandy M
Indian J Hematol Blood Transfus; 2020 Apr; 36(2):399-402. PubMed ID: 32425398
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study.
Ali Z; Ismail M; Rehman IU; Rani GF; Ali M; Khan MTM
Sci Rep; 2023 Aug; 13(1):13592. PubMed ID: 37604857
[TBL] [Abstract][Full Text] [Related]
18. Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias.
Foong WC; Loh CK; Ho JJ; Lau DS
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD013767. PubMed ID: 36637054
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Follow-Up of Patients Undergoing Thalidomide Therapy for Transfusion-Dependent β-Thalassaemia: A Single-Center Experience.
Zhu W; He Y; Huang M; Fu S; Liu Z; Wang X; Li Z; Li X; Chen J; Li Y
Int J Gen Med; 2024; 17():1729-1738. PubMed ID: 38711824
[TBL] [Abstract][Full Text] [Related]
20. A Phase 2 Randomized Controlled Trial of Single-Agent Hydroxyurea Versus Thalidomide Among Adult Transfusion Dependent β Thalassemia Patients.
Bhattacharjee U; Khadwal A; Shafiq N; Lad D; Sharma P; Das R; Shukla P; Jain A; Prakash G; Malhotra P
Indian J Hematol Blood Transfus; 2023 Apr; 39(2):266-275. PubMed ID: 36620489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
